Anifrolumab is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE).
Anifrolumab, sold under the brand name Saphnelo,
It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
Targets Interferon α/β receptor.
Routes of administration Intravenous
A type I interferon receptor antagonist (IFN)
The most common adverse effect was shingles, which occurred in 5% of patients in the low-dose group, to 10% in the high-dose group, and to 2% in the placebo group.